Experience a breakthrough in hematological malignancy testing using a NGS Pan Heme assay co-developed by Roswell Park and Agilent.
Thursday, November 13, 2025
12:00 PM - 12:30 PM EST
Location: Innovation Spotlight Stage #2
This multiomic solution targets DNA mutations (SNV, INDEL, FLT3 ITD, IGH Fusions, CNV) and chimeric RNA fusions, streamlining testing to under three days. The assay offers a future-proof solution by comprehensively targeting relevant mutation types across all heme-related genes. It also integrates automated laboratory and analysis solutions to ensure expedited reporting, minimizing the limitations of NGS testing.